

REMARKS/ARGUMENTS

Claims 2-6, 9-13, 24-28, 31-41, 43, 47, 50-53, 55-62, 65, 67 and 68 are canceled. Claims 1, 7, 8, 14-23, 29, 30, 42, 44-46, 48, 49, 54, 63, 64 and 66 are pending.

Applicants elect Group I.

Applicants request reconsideration of the scope of Group I. Applicants have amended the claims to include compounds in which Q is piperidinyl and pyrrolidinyl rather than only piperidinyl. Otherwise the claims are now limited to the compounds of Group I. Applicants respectfully submit that such an expanded genus is not unduly burdensome to search. Applicants also submit that such a claim is a homogeneous grouping that covers many of Applicant's most active compounds. Applicant's wish to avoid an excessive number of divisional applications.

Applicants further request that claims 63, 64 and 66 be considered. These diseases are established as associated with H3 activity.

Applicants look forward to the Examiner's action.

Respectfully submitted,

/John W. Harbour/

John W. Harbour
Reg. No. 31,365
Attorney for Applicant(s)

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
(732) 524-2169
DATE: June 28, 2006